Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma and Leukocare extend service offering with joint U.S. site
March 22, 2021 05:00 ET | Rentschler Biopharma SE
Leukocare joins Rentschler Biopharma in the U.S., facilitating integrated alliance capabilities and enhanced service for North American clientsClient-focused approach and integration of best-in-class...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
February 26, 2021 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 26, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
February 25, 2021 16:01 ET | MacroGenics, Inc.
MARGENZA™ approved in December 2020; commercial launch expected March 2021July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumabMultiple clinical updates across...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
February 18, 2021 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Names Federica O’Brien to its Board of Directors
February 11, 2021 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
February 11, 2021 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
February 08, 2021 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 08, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
January 11, 2021 08:45 ET | MacroGenics, Inc.
ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
December 16, 2020 16:30 ET | MacroGenics, Inc.
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...
W2Email Logo.jpg
Way2Grow (W2G) Biopharma Company Enters Cannabis Productivity and Announces Plans to Seek Health Canada Approval for Magic Mushroom (Psilocybin and Psilocin) Dealer and Research Licencing
December 15, 2020 08:17 ET | Way2Grow Nurseries
OSOYOOS, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, is pleased to announce it is...